Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
<0.10 EU per 1 μg of the antibody by the LAL method.
Recombinant Mouse CTLA‑4 Fc Chimera (Catalog # 434-CT) under non-reducing conditions only
2.5 µg/106 cells
Mouse splenocytes treated with ConA
Measured by its ability to neutralize CTLA‑4 inhibition of B7‑1/CD80-induced IL‑2 secretion in the Jurkat human acute T cell leukemia cell line. Linsley, P. et al. (1990) Proc. Natl. Acad. Sci. USA 87:5031. The Neutralization Dose (ND50) is typically 2.5-10 µg/mL in the presence of 1 µg/mL Recombinant Mouse CTLA‑4 Fc Chimera, 3 µg/mL Recombinant Human B7‑1/CD80 Fc Chimera, and 10 µg/mL PHA.
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
CTLA‑4 Inhibition of B7‑1/CD80-induced IL‑2 Secretion and Neutralization by Mouse CTLA‑4 Antibody. Recombinant Mouse CTLA‑4 Fc Chimera (Catalog # 434-CT) inhibits Recombinant Human B7‑1/CD80 Fc Chimera (Catalog # 140-B1) induced IL‑2 secretion in the Jurkat human acute T cell leukemia cell line in a dose-dependent manner (orange line), as measured by the Human IL‑2 Quantikine ELISA Kit (Catalog # D2050). Inhibition of Recombinant Human B7‑1/CD80 Fc Chimera (3 µg/mL) activity elicited by Recombinant Mouse CTLA‑4 Fc Chimera (1 µg/mL) is neutralized (green line) by increasing concentrations of Mouse CTLA‑4 Monoclonal Antibody (Catalog # MAB434). The ND50 is typically 2.5-10 µg/mL in the presence of PHA (10 µg/mL).
Preparation and Storage
Reconstitute at 0.5 mg/mL in sterile PBS.
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
CTLA-4 and CD28, together with their ligands B7-1 and B7-2, constitute one of the dominant costimulatory pathways that regulate T and B cell responses. CTLA-4 and CD28 are structurally homologous molecules that are members of the immunoglobulin (Ig) gene superfamily. Both CTLA-4 and CD28 are composed of a single Ig V‑like extracellular domain, a transmembrane domain and an intracellular domain. CTLA-4 and CD28 are both expressed on the cell surface as disulfide-linked homodimers or as monomers. The genes encoding these two molecules are closely linked on human chromosome 2. CTLA-4 was originally identified as a gene that was specifically expressed by cytotoxic T lymphocytes. However, CTLA-4 transcripts have since been found in both Th1 and Th2, and CD4+ and CD8+ T cell clones. Whereas, CD28 expression is constitutive on the surfaces of 95% of CD4+ T cells and 50% of CD8+ T cells and is down regulated upon T cell activation, CTLA-4 expression is upregulated rapidly following T cell activation and peaks approximately 24 hours following activation. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with 20-100-fold higher affinity than CD28. The physiological role of CTLA-4 in T cell costimulation is currently being studied. Recombinant human or mouse CTLA-4/Fc chimera preparations produced at R&D Systems have been shown to bind both B7-1 and B7-2 with high affinity and to inhibit CD28 signalling competitively.
Lenschow, D.J. et al. (1996) Annu. Rev. Immunol. 14:233.
Hathcock, K.S. and R.J. Hodes (1996) Advances in Immunol. 62:131.
R&D Systems personnel manually curate a database that contains references using R&D Systems products.
The data collected includes not only links to publications in PubMed,
but also provides information about sample types, species, and experimental conditions.